152 related articles for article (PubMed ID: 24322903)
1. Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
Saif MW
Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):8-9. PubMed ID: 24322903
[No Abstract] [Full Text] [Related]
2. A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
Aparicio J; García-Mora C; Martín M; Petriz ML; Feliu J; Sánchez-Santos ME; Ayuso JR; Fuster D; Conill C; Maurel J
PLoS One; 2014; 9(1):e82209. PubMed ID: 24416138
[TBL] [Abstract][Full Text] [Related]
3. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Gonçalves A; Gilabert M; François E; Dahan L; Perrier H; Lamy R; Re D; Largillier R; Gasmi M; Tchiknavorian X; Esterni B; Genre D; Moureau-Zabotto L; Giovannini M; Seitz JF; Delpero JR; Turrini O; Viens P; Raoul JL
Ann Oncol; 2012 Nov; 23(11):2799-2805. PubMed ID: 22771827
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
LoConte NK; Holen KD; Schelman WR; Mulkerin DL; Deming DA; Hernan HR; Traynor AM; Goggins T; Groteluschen D; Oettel K; Robinson E; Lubner SJ
Invest New Drugs; 2013 Aug; 31(4):943-8. PubMed ID: 23263993
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.
Necchi A; Lo Vullo S; Raggi D; Perrone F; Giannatempo P; Calareso G; Togliardi E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Colecchia M; Busico A; Pennati M; Zaffaroni N; Mariani L; Salvioni R
Urol Oncol; 2018 Jan; 36(1):8.e1-8.e8. PubMed ID: 28911922
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.
Cascinu S; Berardi R; Sobrero A; Bidoli P; Labianca R; Siena S; Ferrari D; Barni S; Aitini E; Zagonel V; Caprioni F; Villa F; Mosconi S; Faloppi L; Tonini G; Boni C; Conte P; Di Costanzo F; Cinquini M;
Dig Liver Dis; 2014 Feb; 46(2):182-6. PubMed ID: 24189171
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
Naqi N; Ahmad S; Murad S; Khattak J
Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):27-31. PubMed ID: 24333135
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
Ricciardi S; Mey V; Nannizzi S; Pasqualetti G; Crea F; Del Tacca M; Danesi R
Chemotherapy; 2010; 56(4):303-12. PubMed ID: 20714148
[TBL] [Abstract][Full Text] [Related]
9. Use of sorafenib in a corticotropin-secreting pancreatic neuroendocrine carcinoma.
Graham U; Eatock M; Atkinson B
Pancreas; 2014 Jul; 43(5):809-10. PubMed ID: 24921203
[No Abstract] [Full Text] [Related]
10. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
Kindler HL; Wroblewski K; Wallace JA; Hall MJ; Locker G; Nattam S; Agamah E; Stadler WM; Vokes EE
Invest New Drugs; 2012 Feb; 30(1):382-6. PubMed ID: 20803052
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
12. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
13. [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Wang ZY
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):641-5. PubMed ID: 20021856
[No Abstract] [Full Text] [Related]
14. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
Siu LL; Awada A; Takimoto CH; Piccart M; Schwartz B; Giannaris T; Lathia C; Petrenciuc O; Moore MJ
Clin Cancer Res; 2006 Jan; 12(1):144-51. PubMed ID: 16397036
[TBL] [Abstract][Full Text] [Related]
15. [Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer].
Wang Y; Wang L; Liu Y; Yu S; Zhang X; Shi Y; Sun Y
Zhongguo Fei Ai Za Zhi; 2011 Mar; 14(3):239-44. PubMed ID: 21426666
[TBL] [Abstract][Full Text] [Related]
16. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.
Faloppi L; Bianconi M; Giampieri R; Sobrero A; Labianca R; Ferrari D; Barni S; Aitini E; Zaniboni A; Boni C; Caprioni F; Mosconi S; Fanello S; Berardi R; Bittoni A; Andrikou K; Cinquini M; Torri V; Scartozzi M; Cascinu S;
Oncotarget; 2015 Oct; 6(33):35087-94. PubMed ID: 26397228
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Lee JK; Capanu M; O'Reilly EM; Ma J; Chou JF; Shia J; Katz SS; Gansukh B; Reidy-Lagunes D; Segal NH; Yu KH; Chung KY; Saltz LB; Abou-Alfa GK
Br J Cancer; 2013 Aug; 109(4):915-9. PubMed ID: 23900219
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.
El-Khoueiry AB; Ramanathan RK; Yang DY; Zhang W; Shibata S; Wright JJ; Gandara D; Lenz HJ
Invest New Drugs; 2012 Jun; 30(3):1175-83. PubMed ID: 21424698
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Burris H; Rocha-Lima C
Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
[TBL] [Abstract][Full Text] [Related]
20. A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
Sereno M; Moreno V; Moreno Rubio J; Gómez-Raposo C; García Sánchez S; Hernández Jusdado R; Falagan S; Zambrana Tébar F; Casado Sáenz E
Anticancer Drugs; 2015 Oct; 26(9):1004-7. PubMed ID: 26237499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
